BriaCell Therapeutics Corp. (BCTXW)

Market Cap	25.96M +56.4%
Revenue (ttm)	n/a
Net Income	-28.71M
EPS	-33.79
Shares Out	1.88M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	0.0064
Day's Range	n/a
52-Week Range	0.0017 - 0.2500
Beta	2.03
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 13, 2026

About BCTXW

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore Co...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: William Williams
• Employees: 16
• Stock Exchange: NASDAQ
• Ticker Symbol: BCTXW
• Website: https://briacell.com